Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - 49 hours (range 33 to 96 hours) (en)
|
http://linked.open...ugbank/indication
| - For the treatment of severe psoriasis in adults. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - The mechanism of action of acitretin is unknown, however it is believed to work by targeting specific receptors (retinoid receptors such as RXR and RAR) in the skin which help normalize the growth cycle of skin cells. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted. The chain-shortened metabolites and conjugates of acitretin and cis-acitretin are ultimately excreted in the feces (34% to 54%) and urine (16% to 53%). (en)
|
http://linked.open.../drugbank/synonym
| - Acitretin (en)
- Neotigason (en)
- Soriatane (en)
- Acetretin (en)
- Etretin (en)
- Acitretina (en)
- Acitretine (en)
- Acitretinum (en)
- all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid (en)
- (all-e)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid (en)
|
http://linked.open...drugbank/toxicity
| - Oral, rat: LD<sub>50</sub> = >4000 mg/kg. Symptoms of overdose include headache and vertigo. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...nk/proteinBinding
| - Over 99.9% bound to plasma proteins, primarily albumin. (en)
|
http://linked.open...ynthesisReference
| - Yatendra Kumar, "Process for the preparation of acitretin." U.S. Patent US20040192949, issued September 30, 2004. (en)
|
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Oral absorption of acitretin is optimal when given with food, and is linear and proportional with increasing doses from 25 to 100 mg. Approximately 72% (range 47% to 109%) of the administered dose was absorbed after a single 50 mg dose of acitretin was given to 12 healthy subjects. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |